STOK – Stoke Therapeutics Inc.
Stoke Therapeutics, Inc.STOK
$29.37Name : Stoke Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,829,212,288.00
EPSttm : -2.9
Stoke Therapeutics, Inc.
$29.37
1.28%$0.37
STOK — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
26.25
Margin Of Safety %
Put/Call OI Ratio
0.51
EPS Next Q Diff
-0.02
EPS Last/This Y
-3.13
EPS This/Next Y
0.14
Price
29.38
Target Price
45.1
Analyst Recom
1
Performance Q
-23.42
Upside
-225.7%
Beta
1.2
Ticker: STOK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | STOK | 32.67 | 2.12 | 1.83 | 4150 |
| 2026-05-12 | STOK | 32.53 | 2.11 | 13.67 | 4156 |
| 2026-05-13 | STOK | 31.7 | 2.11 | 16.50 | 4156 |
| 2026-05-14 | STOK | 31.38 | 2.11 | 0.43 | 4157 |
| 2026-05-15 | STOK | 30.15 | 2.03 | 0.34 | 4031 |
| 2026-05-18 | STOK | 29.04 | 0.67 | 0.01 | 637 |
| 2026-05-19 | STOK | 29.98 | 0.46 | 5.00 | 825 |
| 2026-05-20 | STOK | 30.29 | 0.50 | 0.43 | 861 |
| 2026-05-21 | STOK | 29.65 | 0.49 | 0.64 | 880 |
| 2026-05-22 | STOK | 29.34 | 0.50 | 0.02 | 899 |
| 2026-05-26 | STOK | 31.05 | 0.46 | 10.40 | 944 |
| 2026-05-27 | STOK | 31.43 | 0.54 | 0.00 | 1000 |
| 2026-05-28 | STOK | 31.59 | 0.53 | 0.09 | 1011 |
| 2026-05-29 | STOK | 30.91 | 0.53 | 6.67 | 1017 |
| 2026-06-02 | STOK | 28.65 | 0.51 | 0.00 | 1004 |
| 2026-06-03 | STOK | 29.42 | 0.50 | 0.00 | 1008 |
| 2026-06-04 | STOK | 30.16 | 0.50 | 0.00 | 1008 |
| 2026-06-05 | STOK | 30.06 | 0.51 | 0.00 | 1009 |
| 2026-06-08 | STOK | 29.01 | 0.51 | 0.00 | 1005 |
| 2026-06-09 | STOK | 29.33 | 0.51 | 999.99 | 1011 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | STOK | 32.64 | -98.5 | - | -3.32 |
| 2026-05-12 | STOK | 32.46 | -98.5 | - | -3.32 |
| 2026-05-13 | STOK | 31.71 | -90.0 | - | -3.32 |
| 2026-05-14 | STOK | 31.36 | -90.0 | - | -3.32 |
| 2026-05-15 | STOK | 30.09 | -90.0 | - | -3.25 |
| 2026-05-18 | STOK | 29.03 | -90.0 | - | -3.25 |
| 2026-05-19 | STOK | 29.97 | -90.0 | - | -3.25 |
| 2026-05-20 | STOK | 30.30 | -90.0 | - | -3.25 |
| 2026-05-21 | STOK | 29.67 | -90.0 | - | -3.25 |
| 2026-05-22 | STOK | 29.33 | -90.0 | - | -3.25 |
| 2026-05-26 | STOK | 31.02 | -90.0 | - | -3.25 |
| 2026-05-27 | STOK | 31.43 | -90.0 | - | -3.25 |
| 2026-05-28 | STOK | 31.58 | -90.0 | - | -3.25 |
| 2026-05-29 | STOK | 30.91 | -90.0 | - | -3.25 |
| 2026-06-01 | STOK | 30.54 | -90.0 | - | -3.25 |
| 2026-06-02 | STOK | 28.62 | -90.0 | - | -3.25 |
| 2026-06-03 | STOK | 29.43 | -90.0 | - | -3.25 |
| 2026-06-04 | STOK | 30.15 | -90.0 | - | -3.25 |
| 2026-06-05 | STOK | 30.02 | -90.0 | - | -3.25 |
| 2026-06-08 | STOK | 29.01 | -90.0 | - | -3.25 |
| 2026-06-09 | STOK | 29.38 | -90.0 | - | -3.25 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | STOK | -1.69 | 7.05 | 25.61 |
| 2026-05-12 | STOK | -1.69 | 7.05 | 26.62 |
| 2026-05-13 | STOK | -1.69 | 7.05 | 26.62 |
| 2026-05-14 | STOK | -1.69 | 7.05 | 26.62 |
| 2026-05-15 | STOK | -1.69 | 7.05 | 26.62 |
| 2026-05-18 | STOK | -1.69 | 1.45 | 26.47 |
| 2026-05-19 | STOK | -1.43 | 1.45 | 26.47 |
| 2026-05-20 | STOK | -1.43 | 1.45 | 26.47 |
| 2026-05-21 | STOK | -1.43 | 1.45 | 26.47 |
| 2026-05-22 | STOK | -1.43 | 1.45 | 26.47 |
| 2026-05-26 | STOK | -1.43 | 6.99 | 26.47 |
| 2026-05-27 | STOK | -1.12 | 6.99 | 26.47 |
| 2026-05-28 | STOK | -1.12 | 6.99 | 26.25 |
| 2026-05-29 | STOK | -1.12 | 6.99 | 26.25 |
| 2026-06-02 | STOK | -1.12 | 6.21 | 26.25 |
| 2026-06-03 | STOK | -1.12 | 6.21 | 26.25 |
| 2026-06-04 | STOK | -1.06 | 6.21 | 26.25 |
| 2026-06-05 | STOK | -1.06 | 6.21 | 26.25 |
| 2026-06-08 | STOK | -0.83 | 6.23 | 26.25 |
| 2026-06-09 | STOK | -0.83 | 6.23 | 26.25 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.79
Avg. EPS Est. Current Quarter
-0.76
Avg. EPS Est. Next Quarter
-0.81
Insider Transactions
-0.83
Institutional Transactions
6.23
Beta
1.2
Average Sales Estimate Current Quarter
5
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
22
Growth Score
31
Sentiment Score
90
Actual DrawDown %
29.4
Max Drawdown 5-Year %
-91.8
Target Price
45.1
P/E
Forward P/E
PEG
P/S
57.02
P/B
4.63
P/Free Cash Flow
EPS
-2.84
Average EPS Est. Cur. Y
-3.25
EPS Next Y. (Est.)
-3.1
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-529.2
Relative Volume
0.63
Return on Equity vs Sector %
-70.5
Return on Equity vs Industry %
-54.3
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.12
EBIT Estimation
◆
STOK
Healthcare
$29.37
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
41.2
Range 1M
30.5%
Sup Dist
3.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-2584.7%
EPS NY
3.2%
52W%
64.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+53.6% upside
Upside
+53.6%
Quality
22
Stoke Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 170
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOK
Latest News
—
Caricamento notizie per STOK…
stock quote shares STOK – Stoke Therapeutics Inc. Stock Price stock today
news today STOK – Stoke Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch STOK – Stoke Therapeutics Inc. yahoo finance google finance
stock history STOK – Stoke Therapeutics Inc. invest stock market
stock prices STOK premarket after hours
ticker STOK fair value insiders trading